[Surrogate and true endpoints in cancer clinical trials]

MLA

T, Nakajima, et al. “[Surrogate and True Endpoints in Cancer Clinical Trials].” Gan to Kagaku Ryoho. Cancerchemotherapy, vol. 27, no. 5, June 2000. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........07d2a1d6f49891142b834e64c3fa8f3a&authtype=sso&custid=ns315887.

APA

T, N., K, O., S, O., & T, Y. (2000). [Surrogate and true endpoints in cancer clinical trials]. Gan to Kagaku Ryoho. Cancerchemotherapy, 27(5).

Chicago

T, Nakajima, Ohta K, Ohyama S, and Yamaguchi T. 2000. “[Surrogate and True Endpoints in Cancer Clinical Trials].” Gan to Kagaku Ryoho. Cancerchemotherapy 27 (5). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........07d2a1d6f49891142b834e64c3fa8f3a&authtype=sso&custid=ns315887.